BCR ABL1 CML/ALL PCR, quant
BCR ABL1 CML/ALL PCR, quant-13551
BCR/ABL
BCR-ABL1
Chronic myelogenous leukemia (CML)
p210
p190
BCR-ABL1 Transcript Detection
This assay can detect three different types of BCR-ABL1 fusion transcripts associated with CML, ALL, and AML:
- e13a2 (previously b2a2) and
- e14a2 (previously b3a2) (major breakpoint, p210)
- e1a2 (minor breakpoint, p190)
Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
Lavender (EDTA), 4mL
ACD-A whole blood
Bone marrow
Cell pellet
Bone marrow - 2.0mL (minimum 1.0 mL)
Dk green Sodium heparin (Na hep), no gel
Yellow ACD-A
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient (preferred) - 48 hours
Refrigerated - >48 hours
- Specimen does not meet collection criteria
- Frozen whole blood or marrow
- Leaking tube
- Clotted blood or marrow
- Grossly hemolyzed
- Otherwise visibly degraded
- Contamination by another specimen
- Containing suspicious foreign material
- PCR testing cannot be added on to a sample that has been opened and/or used for other testing. If the sample has already been used for testing, a new specimen will need to be collected.
Total RNA is isolated from the sample and subject to a real-time, reverse transcriptase polymerase chain reaction (RT-PCR). The PCR primers and probes are specific for BCR-ABL1 e13a2, e14a2 and e1a2 fusion transcripts. The ABL1 transcript is amplified as the control for cDNA quantity and quality. Serial dilutions of a validated positive control RNA with known t(9;22) BCR-ABL1 are used as reference for quantification of BCR-ABL1 relative to ABL1. The numeric BCR-ABL1 level is reported as % BCR-ABL1/ABL1 and the detection sensitivity is 4.5 log below the standard baseline (<0.0032%).
An interpretive report will be included
The e13a2 and e14a2 transcript values are titrated to the current International Scale (IS). The standardized baseline is 100% BCR-ABL1 (IS) and major molecular response (MMR) is equivalent to 0.1% BCR-ABL1 (IS) corresponding to a 3-log reduction. Results should be correlated with appropriate clinical and laboratory information as indicated.
81207
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.